75806-14-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Butynoic acid, 2-[(methoxycarbonyl)amino]-4-(trimethylsilyl)-, methyl ester is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures. Its terminal alkyne group and trimethylsilyl protecting group enable specific chemical reactions that are crucial for the development of new drugs with unique therapeutic properties.
Used in Fine Chemicals Industry:
In the fine chemicals industry, 3-Butynoic acid, 2-[(methoxycarbonyl)amino]-4-(trimethylsilyl)-, methyl ester serves as a reactant in the production of specialty chemicals, such as fragrances, dyes, and other high-value compounds. Its reactivity and functional groups allow for the synthesis of molecules with specific properties, making it an essential component in the development of innovative fine chemicals.
Used in Materials Science:
3-Butynoic acid, 2-[(methoxycarbonyl)amino]-4-(trimethylsilyl)-, methyl ester is utilized in materials science for the synthesis of advanced materials with unique properties. Its incorporation into polymers, for example, can lead to the development of new materials with improved mechanical, thermal, or electrical characteristics, contributing to the advancement of various industries, such as electronics, aerospace, and automotive.

InChI:InChI=1/C10H17NO4Si/c1-14-9(12)8(11-10(13)15-2)6-7-16(3,4)5/h8H,1-5H3,(H,11,13)

Upstream product

• 64356-75-8 Chloro((methoxycarbonyl)amino)acetic acid methyl ester 
• 14630-40-1 Bis(trimethylsilyl)ethyne 
• 143995-55-5 2--2-methoxyethanoate 

Downstream Products

• 944718-26-7 (R)-2-Methoxycarbonylamino-2-(6-methoxy-1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4-(4-sulfo-phenyl)-but-3-ynoic acid methyl ester 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, T

A photocaged, cyclopropene-containing analog of the amino acid neurotransmitter glutamate

Substituted cyclopropenes serve as compact biorthogonal appendages that enable analysis of biomolecules in complex systems. Neurotransmitters, a chemically diverse group of biomolecules that control neuron excitation and inhibition, are not among the systems that have been studied using biorthogonal chemistry. Here we describe the synthesis of cyclopropene-containing analogs of the excitatory amino acid neurotransmitter glutamate starting from a Garner's aldehyde-derived alkyne. The deprotected cyclopropene glutamate was stable in solution but decomposed upon concentration. Appending a light-cleavable group improved the stability of the cyclopropene while simultaneously caging the neurotransmitter. This strategy has the potential to permit deployment of cyclopropene-modified glutamate as a bioorthogonal probe of the neurotransmitter glutamate in vivo with spatiotemporal precision.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases

Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors has led to an acetylene containing series that demonstrates sub-nanomolar potency (Ki) as well as excellent activity in human whole blood. These studies led to the discov

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula: (I); or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α or combinations thereof.